CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity

CAR T cell therapy has shown dramatic clinical success in relapsed or refractory B-ALL and other hematological malignancies. However, the loss of specific antigens, cell fratricide, T cell aplasia, and normal T cell separation are challenges in treating T cell leukemia/lymphoma with CAR T therapy. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jiangzhou, Zhang, Zijian, Cen, Hong, Wu, Han, Zhang, Shangkun, Liu, Jiaxing, Leng, Yingqi, Ren, Anqi, Liu, Xiyu, Zhang, Zhijie, Tong, Xiqin, Liang, Jinjue, Li, Zhe, Zhou, Fuling, Huang, Liang, Qin, You, Yang, Kunyu, Zhang, Tongcun, Zhu, Haichuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502293/
https://www.ncbi.nlm.nih.gov/pubmed/34627328
http://dx.doi.org/10.1186/s13045-021-01178-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502293/
https://www.ncbi.nlm.nih.gov/pubmed/34627328
http://dx.doi.org/10.1186/s13045-021-01178-z

Ejemplares similares